FibroGen IncNASDAQ:FGEN
- LAST PRICE1.0150
- TODAY'S CHANGE (%)-0.0050 (-0.4902%)
- Bid / Lots1.0100/ 24
- Ask / Lots1.0200/ 22
- Open / Previous Close1.0400 / 1.0200
- Day Range
- 52 Week Range
- Volume163,958
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FGEN |
|---|---|---|
| 09:32 ET | 5367 | 1.02 |
| 09:34 ET | 600 | 1.01 |
| 09:36 ET | 8136 | 0.9927 |
| 09:38 ET | 1100 | 0.98 |
| 09:39 ET | 1000 | 0.9801 |
| 09:41 ET | 900 | 0.9801 |
| 09:43 ET | 400 | 0.9801 |
| 09:45 ET | 1200 | 0.99 |
| 09:48 ET | 400 | 0.99 |
| 09:50 ET | 3578 | 0.99 |
| 09:52 ET | 500 | 1.005 |
| 09:54 ET | 4815 | 1.008 |
| 09:56 ET | 15892 | 1.04 |
| 09:57 ET | 10000 | 1.04 |
| 09:59 ET | 3750 | 1.0404 |
| 10:01 ET | 972 | 1.0317 |
| 10:03 ET | 400 | 1.03 |
| 10:06 ET | 500 | 1.03 |
| 10:08 ET | 2024 | 1.0396 |
| 10:10 ET | 358 | 1.03 |
| 10:12 ET | 300 | 1.03 |
| 10:14 ET | 5092 | 1.03 |
| 10:15 ET | 600 | 1.03 |
| 10:17 ET | 1553 | 1.01 |
| 10:19 ET | 100 | 1.01 |
| 10:21 ET | 1295 | 1.01 |
| 10:24 ET | 2897 | 1.01 |
| 10:26 ET | 1605 | 1.01 |
| 10:28 ET | 300 | 1.01 |
| 10:30 ET | 716 | 1 |
| 10:32 ET | 4710 | 1 |
| 10:33 ET | 1500 | 1.005 |
| 10:35 ET | 10187 | 1.01 |
| 10:37 ET | 782 | 1.015 |
| 10:39 ET | 326 | 1.01 |
| 10:42 ET | 800 | 1.01 |
| 10:44 ET | 6273 | 1.01 |
| 10:46 ET | 2650 | 1 |
| 10:48 ET | 1101 | 1 |
| 10:50 ET | 1500 | 1.005 |
| 10:51 ET | 1400 | 1 |
| 10:53 ET | 637 | 1 |
| 10:55 ET | 1262 | 1.005 |
| 10:57 ET | 100 | 1 |
| 11:00 ET | 739 | 1 |
| 11:02 ET | 1500 | 1.005 |
| 11:04 ET | 11683 | 1.015 |
| 11:06 ET | 10161 | 1.025 |
| 11:08 ET | 290 | 1.025 |
| 11:09 ET | 1931 | 1.02 |
| 11:11 ET | 9708 | 1.015 |
| 11:13 ET | 300 | 1.01 |
| 11:15 ET | 1200 | 1.015 |
| 11:18 ET | 1300 | 1.01 |
| 11:20 ET | 747 | 1.01 |
| 11:22 ET | 400 | 1.015 |
Apr 24, 2024
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting, from 4:02PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:02PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
FibroGen Inc | 100.7M | -0.3x | --- |
Karyopharm Therapeutics Inc | 123.5M | -0.8x | --- |
Agenus Inc | 173.9M | -0.7x | --- |
Seres Therapeutics Inc | 112.2M | -0.9x | --- |
Sangamo Therapeutics Inc | 104.4M | -0.4x | --- |
Sutro Biopharma Inc | 258.2M | -1.9x | --- |
Company Information
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Contact Information
- Headquarters
- 409 ILLINOIS STREETSAN FRANCISCO, CA, United States 94158
- Phone
- 415-978-1200
- Fax
- 415-978-1902
Executives
- Independent Chairman of the Board
- James Schoeneck
- Chief Executive Officer, Director, Chief Commercial Officer
- Thane Wettig
- Chief Financial Officer
- Juan Graham
- Senior Vice President and Chief Medical Officer
- Deyaa Adib
- Senior Vice President, China Operations
- Christine Chung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $100.7M |
|---|---|
Revenue (TTM) | $147.8M |
Shares Outstanding | 98.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-2.93 |
Book Value | $-2.07 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -190.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
